Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 4.31 as of 2026-10-06T15:13:23.738Z.
Consensus retrieved: 2026-10-06T14:31:19.420Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:13:23.738Z.
Quote observation: 2026-10-06T15:10:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 127c42f84a692115bc317292f5e8c44ad9cea602a51c3ca4b81ff92f7edcc32f
Forward PE Ratio (4.31) = Dated Quote Price ($6.76) / Consensus Forward EPS ($1.57)
FORWARD PE RATIO
4.31
SECTOR MEDIAN · HEALTHCARE
19.19
median of 165 covered companies
CURRENT VS SECTOR MEDIAN
-77.54%
vs the sector median at left
Nutriband Inc.
Market Cap
$82.17M
Forward PE Ratio
4.31
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Nutriband Inc. (NTRB) | $82.17M | 4.31 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $82.69M | N/A |
| LENSAR Inc (LNSR)vs › | $82.16M | N/A |
| MediciNova, Inc. (MNOV)vs › | $83.18M | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $83.43M | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $80.89M | 8.70 |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.58M | N/A |
| Humacyte, Inc. (HUMA)vs › | $85.04M | N/A |
| Pulmonx Corporation (LUNG)vs › | $80.04M | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $85.53M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
4.3
consensus EPS · fiscal year ending 2027-01-31
At the dated quote price of $6.76, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-01-31 | $1.57 | $1.57 – $1.57 | 1 | 4.3x |
| 2028-01-31 | $3.66 | $3.66 – $3.66 | 1 | 1.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
